Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis

Published:2020-07-09 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Yang Kaili,Li Jiarui,Bai Chunmei,Sun Zhao,Zhao Lin

Funder

National Natural Science Foundation of China

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference60 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin Proc,2008

3. Lung cancer: current therapies and new targeted treatments;Hirsch;Lancet,2017

4. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy;Kazandjian;Oncologist,2016

5. FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond;Pai-Scherf;Oncologist,2017

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors;Journal of Thoracic Imaging;2024-08-27

2. Bone metastasis prediction in non-small-cell lung cancer: primary CT-based radiomics signature and clinical feature;BMC Medical Imaging;2024-08-05

3. Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer;Frontiers in Immunology;2024-06-18

4. Bone metastasis prediction in non-small-cell lung cancer: primary CT-based radiomics signature and clinical feature;2024-04-09

5. NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy;Frontiers in Immunology;2024-02-07